NCT05338476View on ClinicalTrials.gov

A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

July 12, 2018

Primary Completion Date

August 1, 2018

Study Completion Date

September 18, 2018

Conditions

Healthy

Interventions

DRUG

Midazolam

Administered orally.

DRUG

Selpercatinib

Administered orally.

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Collaborators (1)

Loxo Oncology, Inc.

All Listed Sponsors

collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY